Détail de l'auteur
Documents disponibles écrits par cet auteur (291)
Rapport
This report presents the key activities performed by the EMCDDA and Europol in 2014, with details on all the relevant activities in support of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and c[...]Rapport
This report presents the key activities performed by the EMCDDA and Europol in 2017 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, i[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide, commonly known as CUMYL-4CN-BINACA, through a joint assessment. The two or[...]Rapport
In April 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine, commonly known as MT-45. The two organisations concluded that sufficient information had been [...]Rapport
In May 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, commonly known as alpha-pyrrolidinovalerophenone (alpha-PVP), through a joint assessment. The two org[...]Rapport
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), through a joint assessment. The two organisat[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine, commonly known by the abbreviation '25I-NBOMe', submitted in December 2013 to the Council of the EU, the European Commission an[...]Rapport
In February 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance, 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (commonly known by the abbreviation 4,4′-DMAR). The two organisations concluded th[...]Rapport
At the end of 2011 and in 2012, the EMCDDA and Europol examined the available information on a new psychoactive substance, 4-methylamphetamine. The two organisations concluded that sufficient information had been accumulated to merit the product[...]Rapport
At the end of September 2012, the EMCDDA and Europol examined the available information on a new psychoactive substance 5-(2-aminopropyl)indole (commonly known by the abbreviation '5-IT'), through a joint assessment. The two organisations conclu[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the [...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the EMCDDA and[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the availabl[...]Rapport
In May 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), through a joint assessment. The two organisations[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PINACA, through a joint asses[...]Rapport
In February 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA, through a joint assessment.[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint [...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint asses[...]Rapport
In September 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, commonly known as acryloylfentanyl, through a joint assessment. The two organisations [...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide, commonly known as 4-fluoroisobutyrylfentanyl (4F-iBF), through a joint ass[...]Rapport
In September 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (acetylfentanyl), through a joint assessment. The two organisations concluded that[...]Rapport
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), through a joint assessment. The two organis[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran-2-carboxamide, commonly known as tetrahydrofuranylfentanyl (THF-F), through a [...]Rapport
Isotonitazene is a synthetic opioid analgesic monitored by the EMCDDA as a new psychoactive substance through the European Union Early Warning System since 2019. Based on potential public health risks, an initial report has been prepared and sub[...]Rapport
These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 20[...]Rapport
This paper is part of the EMCDDA activity around the development and improvement of drug supply indicators, with a focus on drug-related homicide. It builds upon the 2017 review of the academic research and data sources on drug-related homicide [...]Rapport
This report is a rapid and preliminary analysis of the impact of COVID-19 on selected online markets. Three relatively large darknet markets were reviewed for the purposes of this study, selected because of their importance to the EU market and [...]Rapport
This report was compiled as a supporting document for the evaluation of the 2005-12 EU drugs strategy and its two action plans: 2005-08 and 2009-12. It reviews the main trends and changes in the European drug situation and in the responses devel[...]Rapport
Since the beginning of 2020, the world has been experiencing an unprecedented public health emergency caused by the coronavirus disease (COVID-19) pandemic, which has led to the progressive introduction of social distancing and other control mea[...]Rapport
FRANÇAIS : Depuis le début de l'année 2020, le monde connaît une situation sanitaire sans précédent causée par la pandémie de coronavirus (COVID-19), qui a conduit à l'introduction progressive de mesures de distanciation sociale et d'autres mes[...]Rapport
Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this outbreak for drug ser[...]Rapport
Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects and implications of this pandemic for people w[...]Rapport
Brief interventions are psychosocial techniques designed to help recipients recognise harmful patterns of substance use, and to motivate and support them to address that use. Studies suggest that brief interventions in an emergency department ma[...]Périodique
OEDT = EMCDDA ; I. GIRAUDON ; G. MENA ; J. MATIAS ; J. VICENTE | Lisbon : OEDT / EMCDDA | Technical reports | 2014This study reveals the substantial levels of morbidity related to cocaine use, translated into the large number of cocaine cases seen in various emergency settings in European countries. This health burden is often not captured by other traditio[...]Rapport
OEDT = EMCDDA ; D. MANSFIELD ; A. CUNNINGHAM ; L. LANIEL ; P. GRIFFITHS ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Ad hoc publication | 2020This paper provides an analysis of the available data that suggest that a methamphetamine industry is rapidly being established in Afghanistan. The analysis provided is based on information from key informants, documentary sources and the analys[...]Rapport
Ce rapport tente de combler une partie du manque de connaissance sur le trafic, la consommation des drogues illicites et des médicaments psychotropes en Afrique. Il dresse un inventaire des organismes spécialisés intervenants dans le champ spéci[...]Rapport
This study estimates how much 22 European countries spent on drug-law offenders in prisons during the last decade. Based on this, an estimate for public expenditure on drug-law offenders at the European level was made.Rapport
This report presents estimates of aggregate market size for the different drugs at EU and European level and describes in detail how these estimates were achieved. Country level estimates are not reported given the uncertainty around some of the[...]Rapport
This report includes estimates of the total size of the retail drug market in the European Union in 2017 for cannabis, heroin, cocaine, amphetamines and MDMA.Rapport
OEDT = EMCDDA ; A. SARASA-RENEDO ; G. BARRIO ; L. MONTANARI ; B. GUARITA ; L. DE LA FUENTE ; M. J. BRAVO ; J. VICENTE | Lisbon : OEDT / EMCDDA | Technical reports | 2015FRANÇAIS : Ce rapport décrit les tendances en matière d'injection de drogues dans les États membres de l'UE, la Norvège et la Turquie entre 2000 et 2011, à travers une analyse des données relatives aux personnes recevant un traitement médicamen[...]Rapport
OEDT = EMCDDA, Organisateur de réunion ; Groupe Pompidou, Organisateur de réunion ; G. V. STIMSON ; A. JUDD ; P. D. A. COHEN ; P. LAZAROV ; R. SIMON ; C. MORENO IRIBAS ; M. URTIAGA DOMINGUEZ ; B. OLSSON ; P. GRIFFITHS ; M. FARRELL ; S. HOWES ; A. DOMINGO-SALVANY ; C. RICHARDSON ; P. Y. BELLO ; G. CHENE ; M. FRISCHER ; K. PÜSCHEL ; M. DAVOLI ; H. SAELAN ; C. TAYLOR ; D. J. KORF ; L. KRAUS ; W. KIRSCHNER ; Z. ELEKES ; J. SIEROSLAWSKI ; A. ZIELINSKI ; D. NOLIMAL ; R. HARTNOLL | Lisbon : OEDT / EMCDDA | Monographs, ISSN 1606-1691 | 1997FRANÇAIS : Cette monographie, qui présente la plupart des communications du séminaire "Addiction prevalence estimation: methods and research strategies", Strasbourg, juin 1996, est centrée sur la question : comment obtenir des estimations qui [...]Rapport
OEDT = EMCDDA ; CAPPI R. | 1993FRANÇAIS : La réduction de la demande des drogues a été identifiée comme la première priorité de l'Observatoire Européen des Drogues et des Toxicomanies dans le cadre de l'étude de faisabilité de l'OEDT. C'est dans ce contexte qu'a été réalisée[...]Rapport
L'étude a révélé que l'information non-gouvernementale relative à la problématique évoquée était fortement sous-exploitée, principalement par manque de ressources techniques et d'appuis méthodologiques adaptés. Trois principes fondamentaux ont é[...]Document multimédia
"EU Drug Market: Amphetamine" describes the European amphetamine market from production and trafficking, to distribution and use. It details the processes, materials and actors involved at different stages and levels of the market. Taking a thre[...]Rapport
This resource offers a strategic and top-level summary for policymakers and decision-makers, to support the development and implementation of policies and actions in Europe, based on a robust understanding of the current drug landscape and emerg[...]Document multimédia
'EU Drug Market: Cannabis' describes the European cannabis market from production and trafficking, to distribution and use. It details the processes, materials and players involved at different stages and levels of the market. The module takes a[...]Rapport
Document multimédia
What are the latest changes in the EU opioids market? How are global geopolitical developments impacting supply? Are heroin trafficking routes changing? To what extent do synthetic opioids pose a threat to Europe? These are among the issues expl[...]Rapport
What effect is COVID-19 having on the drug market in the EU? This joint publication from the EMCDDA and Europol analyses the impact of the pandemic on the market for the main drug types (cannabis, heroin, cocaine, amphetamines, NPS), including d[...]Rapport
Rapport
The EU Drug Markets Report 2019 is the third comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol. The analysis presented in this report spans numerous topics such as the links between drugs and other cr[...]Rapport
FRANÇAIS : Le présent rapport analyse le phénomène du marché des drogues illicites dans le contexte plus large des nouvelles tendances en matière de consommation de drogue, des facteurs culturels et sociaux et des liens avec la criminalité. Les[...]Rapport
The EU drug markets report is the first comprehensive overview of illicit drug markets in the European Union. It covers issues such as production, consumer markets, trafficking, organised crime and policy responses, along with a review of the ma[...]Rapport
This Manual is a joint production by the EMCDDA and the Prevention Standards Partnership, and presents and describes basic and expert level quality standards for drug prevention. The standards cover all aspects of drug prevention work, including[...]Rapport
The aim of this 'quick guide' is to make practical information on prevention quality standards available outside the European Union. A condensed version of EMCDDA Manual 7, it includes a description of the eight stages involved in the drug preve[...]Document multimédia
FRANÇAIS : La diversification de l'offre et de l'usage de drogues crée de nouvelles problématiques pour la politique en matière de drogue, de soins et de santé en Europe. [...] Ce rapport fournit la dernière vue d'ensemble existante de la situa[...]Rapport
FRANÇAIS : Ce bref rapport analyse les similitudes entre les mesures nationales dans le domaine du traitement de substitution avec des substances sous contrôle et les obligations posées par les Conventions Internationales. (Résumé d'auteur) [...]Rapport
When a new psychoactive substance appears on the market, legislators need to choose whether to bring it under control of the drug laws, and for public health reasons they may need to do so quickly. A comparative study of the systems and procedur[...]Rapport
ENGLISH: This handbook has been developed with the primary purpose of providing specific reference material for the European Prevention Curriculum (EUPC) training courses. It also serves to provide a more general introduction to prevention scie[...]Rapport
OEDT = EMCDDA ; L. MONTANARI ; L. ROYUELA ; M. ROSA ; J. VICENTE | Lisbon : OEDT / EMCDDA | Technical reports | 2014This is a first common questionnaire on drug use among prisoners at European level. The questionnaire is the results of two years of work in the field of drugs and prison, which has included the agreement on a methodological framework or monitor[...]Rapport
OEDT = EMCDDA ; L. MONTANARI ; V. MRAVCIK ; K. GROHMANNOVA ; L. ROYUELA | Lisbon : OEDT / EMCDDA | Technical reports | 2017This is the final version of the questionnaire on drug use among prisoners at European level. The questionnaire is the results of several years of work in the field of drugs and prison, which has included the agreement on a methodological framew[...]Rapport
OEDT = EMCDDA ; T. NÉFAU ; E. LEFRANÇOIS ; V. DETREZ ; T. SEYLER ; B. GUARITA ; ESCAPE Network | Lisbon : OEDT / EMCDDA | Technical reports | 2021This protocol documents a new approach that has been developed to monitor substances injected by people who inject drugs through analytically confirmed data at the local level: the analysis of residual content of used syringes. Used syringes con[...]Rapport
This document summarises the main issues concerning evaluation in the field of drug policy. Aimed at those managing rather than undertaking drug policy evaluations, the guide acts as an introduction, providing links to the wider literature. Reco[...]Rapport
This publication consists of a series of workbooks intended to educate programme planners, managers, staff and other decision-makers about the evaluation of services and systems for the treatment of psychoactive substance use disorders. The obje[...]Chapitre
FRANÇAIS : De nombreux pays ont récemment adopté une «stratégie nationale antidrogue». Cette partie est axée sur les plans prévoyant l'évaluation de ces stratégies, qui a été menée à l'échelle européenne pour la première fois grâce aux travaux [...]Rapport
European Centre for Disease Prevention and Control ; OEDT = EMCDDA | Stockholm : ECDC (European Centre for Disease Prevention and Control) | Technical report | 2011This is the first of two technical reports that present the evidence behind the "Guidance on the prevention and control of infectious diseases among people who inject drugs". The evidence presented here focuses on the effectiveness (and in some[...]Rapport
European Centre for Disease Prevention and Control ; OEDT = EMCDDA | Stockholm : ECDC (European Centre for Disease Prevention and Control) | Technical report | 2011The aim of the literature review presented in this report was to provide evidence to inform the recommendations made by ECDC and the EMCDDA in the 2011 'Guidance on the prevention and control of infectious diseases among people who inject drugs'[...]Chapitre
This Selected issue looks both at drug use among socially excluded populations (prisoners, immigrants, the homeless, sex workers and vulnerable young people) and social exclusion among drug addicts.Rapport
OEDT = EMCDDA ; J. MOUNTENEY ; T. GROSHKOVA ; D. THANKI ; A. CUNNINGHAM ; M. RYCHERT | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2014Concerns about the availability and use of methamphetamine in Europe have been growing for some time. Historically, the use of methamphetamine has been confined largely to the Czech Republic and Slovakia; however, recent signs of the spread of m[...]Rapport
OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. CHRISTIE ; S. SOLA ; A. ALMEIDA ; R. JORGE ; J. DE MORAIS ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Rapid communication | 2018In this update from the EU Early Warning System, the EMCDDA aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency's early warning and risk-assessment activities. This report cov[...]Rapport
OEDT = EMCDDA ; J. MOUNTENEY ; M. EVANS-BROWN ; I. GIRAUDON | Lisbon : OEDT / EMCDDA | Technical reports | 2012The EMCDDA Trendspotter case study on Fentanyl in Europe was undertaken during September and October 2012. It culminated in an expert meeting in Lisbon on 9-10 October 2012. The aim of the study was to increase understanding of the availability [...]Rapport
OEDT = EMCDDA ; C. COSTA STORTI ; D. FRASQUILHO ; G. BURKHART ; M. MOREIRA | Lisbon : OEDT / EMCDDA | EMCDDA Papers, ISSN 2315-1463 | 2014The economic crisis that Europe experienced in 2008 and later presented a grave challenge to public finances. Countries responded to this by undertaking fiscal consolidation. By examining public expenditure in the areas where most drug-related a[...]Rapport
Rapport
This report presents the overview of the drug phenomenon in France, covering drug supply, use and public health problems, as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided t[...]Rapport
In November 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-carboxamide, commonly known as furanylfentanyl, through a joint assessment. Furanylf[...]Rapport
This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 23 May 2017. On the ba[...]Rapport
OEDT = EMCDDA ; ONUDC / UNODC | New York : UNODC/UNODCCP | Programme mondial d'évaluation de l'abus de drogues / Global Assessment Programme on drug abuse (GAP) | 2007The number of people seeking treatment for drug problems is a leading indicator of drug use patterns and prevalence. Data collected from this group offer a valuable 'window' onto an otherwise hidden population and a means of assessing the perfor[...]Rapport
Prices are an essential element of the illicit drug market, from both a supply and demand perspective. They are an indicator of drug availability and are an important tool for understanding the workings of drug supply mechanisms. They may also b[...]Rapport
OEDT = EMCDDA ; C. KROGER ; H. WINTER ; R. SHAW ; L. LEONE | Lisbon : OEDT / EMCDDA | Manuals | 2012The EMCDDA first published the Guidelines for the evaluation of drug prevention in 1998 to respond to a need expressed by professionals and policymakers to have a tool and stimulus to evaluate prevention interventions in Europe. These guidelines[...]Rapport
ENGLISH : The main objective of the guidelines is to provide a European audience with basic information on the options, elements and procedures of drug-related treatment evaluation. The target readership includes professionals working in treat[...]Rapport
Prevalence of problem drug use (PDU) is one of five key indicators used by the EMCDDA to provide more comparable, scientifically based estimates of the prevalence of more severe patterns of drug use that cannot be reliably measured by surveys. T[...]Rapport
FRANÇAIS : En juin 1997, le Conseil de l'Union Européenne voulant suppléer aux différences de législation sur les nouvelles drogues de synthèse dans les Etats membres de l'Union Européenne, a adopté une action commune permettant l'échange d'in[...]Rapport
At least 1.1 million Europeans are estimated to have received treatment for drug dependence during 2009, mostly through opioid substitution, detoxification and psychosocial interventions, delivered in a variety of settings. While more than half [...]Rapport
OEDT = EMCDDA ; J. HILLEBRAND ; D. OLSZEWSKI ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Thematic Papers, ISSN 1725-5767 | 2006FRANÇAIS : Cette étude thématique met en évidence un intérêt croissant des jeunes européens pour l'expérimentation des champignons hallucinogènes. Les enquêtes menées auprès d'élèves scolarisés (15-16 ans) montrent que la prévalence de l'usage[...]Document multimédia
FRANÇAIS : L'OEDT vient d'ajouter sur son site une section présentant une vue d'ensemble des pratiques de réduction des méfaits pour 30 pays européens. Pour chacun des pays, on peut trouver : • une description du contexte national ; • une de[...]Document multimédia
The Health and social responses to drug problems: a European guide 2021 was developed to support practitioners and policymakers in tackling the negative consequences of drug use. The guide is composed of four sets of miniguides that look at resp[...]Rapport
FRANÇAIS : Comment répondre aux problèmes des héroïnomanes âgés ? Comment lutter contre les décès causés par le fentanyl et ses dérivés extrêmement puissants ? Comment prévenir les risques dus à la consommation d'alcool et de drogues lors des f[...]Rapport
OEDT = EMCDDA ; A. PIRONA ; A. ATKINSON ; H. SUMNALL | Lisbon : OEDT / EMCDDA | Rapid communication | 2016FRANÇAIS : Bien que l'usage de NPS en Europe demeure relativement faible, l'EMCDDA s'alarme des risques liés à la consommation de ces substances. Les données récentes mettent en évidence que les NPS sont à l'origine d'urgences hospitalières et [...]Rapport
This report provides an overview of principles of effective health risk communication for a drug checking service audience. The contents of this report are based on the findings of international evidence reviews of health risk communication, com[...]Rapport
OEDT = EMCDDA ; M. HICKMAN, Éditeur scientifique ; N. K. MARTIN, Éditeur scientifique ; I. GIRAUDON ; L. WIESSING ; D. HEDRICH ; E. KALAMARA ; P. GRIFFITHS ; R. SIMON | Lisbon : OEDT / EMCDDA | Insights, ISSN 1606-1683 | 2016FRANÇAIS : L'hépatite C est une maladie infectieuse du foie causée par le virus de l'hépatite C (VHC) qui peut être transmis par le sang. Environ 115 millions de personnes à travers le monde ont été infectées à un moment donné de leur vie par l[...]Rapport
OEDT = EMCDDA ; D. HEDRICH, Coordonnateur | 2019Hepatitis C virus (HCV) infection has a high prevalence in people who inject drugs (PWID) in Europe, although HCV infection is both preventable and curable. Effective interventions that target the prevention of HCV transmission and the treatment[...]Rapport
OEDT = EMCDDA ; I. UJVARY ; M. EVANS-BROWN ; A. GALLEGOS ; G. PLANCHUELO ; J. DE MORAIS ; R. CHRISTIE ; R. JORGE ; R. SEDEFOV | Lisbon : OEDT / EMCDDA | Technical reports | 2023The markets for hexahydrocannabinol (HHC) and related semi-synthetic cannabinoids (SSC) are rapidly evolving areas with relatively limited information currently available. The European situation presented in Section 1 can only provide an overvie[...]Rapport
OEDT = EMCDDA ; J. MOUNTENEY ; M. RUIZ ; A. BO ; T. GROSHKOVA ; J. MATIAS ; L. VANDAM ; F. CARDOSO ; R. CHRISTIE ; L. MONTANARI ; I. GIRAUDON ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Rapid communication | 2017This report provides a first look at the emergence of more problematic forms of use of new psychoactive substances among a range of demographic groups, including opioid and amphetamine injectors, prisoners, the homeless and men who have sex with[...]Rapport
OEDT = EMCDDA ; European Centre for Disease Prevention and Control | Lisbon : OEDT / EMCDDA | Joint publications | 2012ENGLISH: In response to a notified increase in HIV cases among injecting drug users (IDU) in Greece and Romania, the European Commission asked the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for [...]Rapport
FRANÇAIS : Les données des services d'urgences hospitalières montrent que, chaque année, en Europe, des milliers de personnes subissent des empoisonnements et autres problèmes liés aux drogues qui nécessitent une forme d'assistance médicale. Da[...]Rapport
Contingency management (CM) is a general behavioural intervention technique used in the treatment of drug dependence to systematically arrange consequences and it is designed to weaken drug use and strengthen abstinence. The main elements of CM[...]Rapport
OEDT = EMCDDA ; A. PIRONA ; L. MONTANARI ; I. GIRAUDON ; J. MATIAS ; K. OIEN ; L. VANDAM ; T. SURMONT ; B. GUARITA ; F. MATHIS ; J. MOUNTENEY ; K. NATONIEWSKA ; S. SLEIMAN ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Ad hoc publication | 2021Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way we live, with European countries having to introduce unprecedented measures to protect public health. As with all areas of life, drug consumption, related harms and dru[...]Rapport
OEDT = EMCDDA ; J. FOUNTAIN ; G. BURKHART ; L. MONTANARI | Lisbon : OEDT / EMCDDA | Technical reports | 2017This report provides an overview of the various types of brief interventions (BIs) currently used in European countries in the field of substance use, particularly illicit drugs. Targeted at policymakers and practitioners alike, it covers more t[...]Rapport
This publication provides a practical introduction to the area of quality standards and quality assurance mechanisms and the key steps involved in their implementation in drug services and systems. The primary audience for this guide is those re[...]Rapport
This report provides a summary of the key findings from the assessment of progress of the EU Member States, Norway and Turkey towards the implementation of the revised drug supply indicators, as developed by the EMCDDA in line with the Council c[...]